Phyllis Whiteley, PhD., is a Venture Partner with Mohr Davidow Ventures and has been working with our portfolio companies since 2008. Phyllis’ career is founded on her passion for personalized medicine, global healthcare, and transformative life science innovations. She has founded and built multiple companies in the United States and abroad.
As a Venture Partner at Mohr Davidow Ventures, she provides hands-on leadership in building, investing, and creating companies in diagnostics, life science tools, digital health, and personalized medicine including Verinata Health, (acquired by NASDAQ: ILMN), Sequenta (acquired by Adaptive Biotechnologies), and DVS (acquired by NASDAQ:FLDM). As an Entrepreneur – in - residence at 5AM Ventures, Dr. Whiteley co-founded Anaphore, Inc. (now Bird Rock Bio).
Her executive expertise includes strategic planning, financing, partnerships, restructuring, building executive teams and M&A. Prior to joining Mohr Davidow Ventures, Phyllis was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for Roche. Over her ten-year career with Roche she held various positions in Business Development based in Basel, Switzerland coupled with R&D leadership positions in the US. Phyllis also held a Senior Research Immunology role with Merck.
Phyllis currently serves on multiple boards including Balance Therapeutics, RainDance Technologies, Analyte Health (Chair), the Personalized Medicine Coalition (emeritus), UCSF Leadership Council for Global Health, and Springboard Enterprises, where she mentors women executives. Dr. Whiteley serves (Chair) on the advisory board for the University of Texas Horizon Fund. She is also a Global Social Benefit Incubator (GSBI) mentor at Santa Clara University in Santa Clara, California.
Facts & Stats
Phyllis holds a BA in Chemistry and Ph.D. in Pharmacology from Washington University, St. Louis, Missouri.
Phyllis’ research has resulted in multiple new chemical entities and publications.
Phyllis is committed to the mentorship of CEOs and entrepreneurs worldwide